CRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?
By
[email protected] (Brendan Coffey)
1d agoen
Source
BarsCRISPR Therapeutics vs. Viking Therapeutics: Is a Gene-Editing or Weight Loss Focused Stock Is a Better Buy in 2026?fool.comOne has FDA approval and revenue; the other is pre-commercial but debt-free. Both face distinct risks that could reshape your biotech bet.
You might also wanna read
FDA Draft Guidance Allows Gene Therapy Companies to Leverage Existing Data for Faster Product Approvals
The FDA released a new draft guidance on June 2 titled "Leveraging Prior Knowledge in the Development of Human Gene Therapy Products Incorpo
jdsupra.com·26d ago
CRISPR’s next act: the companies editing the epigenome to treat disease
nature.com·9d ago
Manufacturing and regulatory hurdles threaten cell and gene therapy progress
The article discusses how manufacturing and regulatory challenges are hindering the progress of cell and gene therapies, particularly in can
medium.com·24d ago
Daily briefing: Editing the epigenome with CRISPR to treat disease
Nature Communications·9d ago
Navigating the Complex Landscape of Cell and Gene Therapy Manufacturing
bioprocessintl.com·22d ago
https://doi.org/10.1093/nar/gkag414
doi.org·1mo ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.